文献速递胸部肿瘤消化系统肿瘤

Adagrasib(MRTX849)在晚期KRASG12C实体瘤患者中的首次人体I/IB期剂量探索研究(KRYSTAL-1)

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
PubMed 文献 · J Clin Oncol · 2022-02-15

这项首次人体I/IB期研究评估了口服KRASG12C共价抑制剂adagrasib在晚期KRASG12C突变实体瘤患者中的安全性、药代动力学和临床活性。25例患者入组,推荐II期剂量为600 mg每日两次;在600 mg每日两次治疗的15例可评估非小细胞肺癌患者中,8例(53.3%;95% CI,26.6至78.7)达到确认的部分缓解,中位缓解持续时间16.4个月(95% CI,3.1至不可估计)。结论认为600 mg每日两次耐受良好并显示出抗肿瘤活性。

要点

  • 推荐II期剂量为adagrasib 600 mg每日两次,基于安全性、耐受性和观察到的药代动力学特征确定。
  • 600 mg每日两次治疗的15例可评估KRASG12C突变非小细胞肺癌中,8例(53.3%)达到确认部分缓解。
  • RP2D下最常见任何级别治疗相关不良事件为恶心(80.0%)、腹泻(70.0%)、呕吐(50.0%)和疲乏(45.0%)。

核心结论

  • Adagrasib 600 mg每日两次耐受良好,并在携带KRASG12C突变的晚期实体瘤患者中显示出抗肿瘤活性。

研究设计与样本

  • 首次人体I/IB期剂量探索研究,采用加速滴定设计,在观察到预设毒性程度或达到目标adagrasib暴露时转为改良毒性概率区间设计。
  • 25例晚期KRASG12C突变实体瘤患者入组并接受至少一剂adagrasib,给药方案为150 mg每日一次、300 mg每日一次、600 mg每日一次、1,200 mg每日一次或600 mg每日两次口服。
  • 评估安全性、药代动力学和临床活性。

主要发现

  • 推荐II期剂量为600 mg每日两次,基于安全性、耐受性和观察到的药代动力学特征确定;未正式定义最大耐受剂量。
  • 中位随访19.6个月后,600 mg每日两次治疗的15例RECIST可评估KRASG12C突变非小细胞肺癌患者中,8例(53.3%;95% CI,26.6至78.7)达到确认的部分缓解。
  • 中位缓解持续时间为16.4个月(95% CI,3.1至不可估计),中位无进展生存期为11.1个月(95% CI,2.6至不可估计)。
  • 600 mg每日两次治疗的2例KRASG12C突变结直肠癌患者中,1例达到部分缓解(缓解持续时间4.2个月)。
  • RP2D下最常见的任何级别治疗相关不良事件为恶心(80.0%)、腹泻(70.0%)、呕吐(50.0%)和疲乏(45.0%);最常见的3-4级治疗相关不良事件为疲乏(15.0%)。

关键数值与推荐

  • 推荐II期剂量:adagrasib 600 mg每日两次。
  • 600 mg每日两次治疗的RECIST可评估KRASG12C突变非小细胞肺癌患者:确认部分缓解8/15例(53.3%;95% CI,26.6至78.7)。
  • 中位缓解持续时间16.4个月(95% CI,3.1至不可估计);中位无进展生存期11.1个月(95% CI,2.6至不可估计)。
  • RP2D下任何级别治疗相关不良事件:恶心80.0%、腹泻70.0%、呕吐50.0%、疲乏45.0%;3-4级治疗相关不良事件:疲乏15.0%。

临床怎么用

  • 原文结论为adagrasib 600 mg每日两次耐受良好并在KRASG12C突变晚期实体瘤中显示抗肿瘤活性,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non-small-cell lung cancer, colorectal cancer, and other solid tumors harboring the KRASG12C mutation. MATERIALS AND METHODS: Patients with advanced KRASG12C-mutant solid tumors were treated with adagrasib 150 mg orally once daily, 300 mg once daily, 600 mg once daily, 1,200 mg once daily, or 600 mg orally twice a day using an accelerated titration design, which transitioned to a modified toxicity probability interval design when a predefined degree of toxicity was observed or target adagrasib exposure was achieved. Safety, pharmacokinetics, and clinical activity were evaluated. RESULTS: Twenty-five patients were enrolled and received at least one dose of adagrasib. The recommended phase II dose (RP2D) was 600 mg twice a day on the basis of safety, tolerability, and observed pharmacokinetics properties. No maximum tolerated dose was formally defined. After a median follow-up of 19.6 months, eight of 15 patients (53.3%; 95% CI, 26.6 to 78.7) with RECIST-evaluable KRASG12C-mutant non-small-cell lung cancer treated at 600 mg twice a day achieved a confirmed partial response. The median duration of response was 16.4 months (95% CI, 3.1 to not estimable). The median progression-free survival was 11.1 months (95% CI, 2.6 to not estimable). One of two patients with KRASG12C-mutant colorectal cancer treated at 600 mg twice a day achieved a partial response (duration of response, 4.2 months). At the RP2D, the most common treatment-related adverse events (any grade) were nausea (80.0%), diarrhea (70.0%), vomiting (50.0%), and fatigue (45.0%). The most common grade 3-4 treatment-related adverse event was fatigue (15.0%). CONCLUSION: Adagrasib 600 mg twice a day was well tolerated and exhibited antitumor activity in patients with advanced solid tumors harboring the KRASG12C mutation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ou SI, Jänne PA, Leal TA, et al. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1). J Clin Oncol. 2022. PMID: 35167329. doi:10.1200/JCO.21.02752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。